Wilkinson, D.
Gallagher, I. J.
McNelly, A.
Bear, D. E.
Hart, N.
Montgomery, H. E.
Le Guennec, A.
Conte, M. R.
Francis, T.
Harridge, S. D. R.
Atherton, P. J.
Puthucheary, Z. A.
Funding for this research was provided by:
National Institute of Health Research’s Comprehensive Biomedical Research Centre at University College London Hospitals (BRC202 rev/CM/AM/101320; RCF236/AMcN/2015)
J P Moulton Charitable Foundation (JM29/04/ 14; JM02/06/15)
Intensive Care Foundation, UK (New Investigator Award, A. S. McN.)
North Thames Local Clinical Research Network
London South Local Clinical Research Network
American Society of Parenteral and Enteral Nutrition Rhoads Research Foundation
Article History
Received: 15 April 2023
Accepted: 1 November 2023
First Online: 9 November 2023
Competing interests
: This work was supported (in part) by the ASPEN Rhoads Research Foundation. D. E. B. reports speaker fees from, Baxter Healthcare; advisory board fees from Baxter Healthcare;. N. H. reports unrestricted grants from Philips and ResMed outside the direct area of work commented on here with the funds held and managed by Guy’s and St Thomas’ NHS Foundation Trust; financial support from Philips for the development of MYOTRACE technology that has a patent filed in Europe (US pending) outside the area of work commented on here; personal fees for lecturing from Philips-Respironics, Philips, ResMed, and Fisher-Paykel both within and outside the area of work commented on here; N. H. is on the Pulmonary Research Advisory Board for Philips outside the area of work commented on here with the funds for this role held by Guy’s and St Thomas’ NHS Foundation Trust. H. E. M. has a patent, “The Use of Inhibitors of the Renin-Angiotensin System,” which relates in part to the prevention of muscle wasting, issued. Z. A. P. reports personal fees from Faraday Pharmaceuticals, Lyric Pharmaceuticals,Bioage, Fresenius Kabi, Nestlé, Orion, and GlaxoSmithKline, outside the submitted work. None declared (DW, IJG, AM,PJA, ALG, MRC, TF, SDR).